AstraZeneca (AZ) has provided support to AHA to fund up to 10 researchers over 12 months to answer questions that are of strategic importance for scientific progress in three broad areas: heart failure, HDL, and predictors of CVD.
American Heart Association Cardiovascular Genome-Phenome Study (CVGPS)
The Cardiovascular Genome-Phenome Study (CVGPS) is a collaborative effort, spearheaded by the American Heart Association (AHA), to accelerate the future of cardiovascular medicine. CVGPS combines the power of long-term population studies with the precision of molecular analysis to unravel key distinctions between and within subgroups of patients. The discoveries it generates will point the way toward better-targeted, safer, and more effective treatments, based on a deeper understanding of patients’ characteristics, including e.g. risk profiles and therapeutic needs.
The CVGPS is a collaboration among AHA, Boston University (BU) and the University of Mississippi Medical Center (UMMC), the academic coordinating center homes, respectively, of the Framingham Heart Study (FHS) and the Jackson Heart Study (JHS). The Jackson Heart Study also involves Jackson State University (JSU) and Tougaloo College (TC) as partner institutions.
Through the rich diversity of constituent participant/patient populations, CVGPS research will bring inter-individual and patient-to-patient differences into ever sharper focus for common diseases such as atherosclerosis and hypertension.